secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENvue Medical, Inc. (FEED)
CIK:        0001326706
Form:       8-K
Filed at:   2025-02-14T23:59:59+00:00
Accession:  0001493152-25-006855
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 2.01, 2.03, 3.02, 3.03, 5.02, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NanoVibronix completes reverse merger with ENvue; ENvue holders to own 85% post-conversion
--------------------------------------------------------------------------------

- Closed merger with ENvue Medical on Feb 14, 2025; issued 1,734,995 common shares (19.9% pre-merger) and 57,720 Series X Preferred (convertible 1,000:1, subject to stockholder approval).
- Upon Series X conversion, ENvue holders would own 85% of common stock; existing NAOV holders would own 15%.
- Three directors resigned; Doron Besser (ENvue CEO) and Zeev Rotstein appointed to board; Rotstein named to audit committee.
- Issued $500K senior convertible debenture (8% interest, conversion price $0.4446 with floor $0.0889) to institutional investor.
- Stockholder meeting to be called to approve Series X conversion, new incentive plan (10% of fully-diluted equity), and charter amendment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326706/000149315225006855/0001493152-25-006855-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326706/000149315225006855/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-006855

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer